title: Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy.
abstract: OBJECTIVE
  To determine the degree of metamorphopsia before and 1 year after half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy.
  
  
  METHODS
  This was a retrospective, noncomparative, interventional case series. Forty-five eyes of 45 consecutive patients with chronic central serous chorioretinopathy were evaluated. The degree of metamorphopsia was measured with M-CHARTS before and at 1, 3, 6, 9, and 12 months after half-dose verteporfin photodynamic therapy. The best-corrected visual acuity was also measured.
  
  
  RESULTS
  Forty of the 45 eyes had a complete resolution of the serous retinal detachment at 1 month, 1 eye at 3 months, and 3 eyes at 6 months. The serous retinal detachment in one eye persisted throughout the follow-up period. The mean horizontal metamorphopsia score improved significantly from 0.61 ± 0.52° at baseline to 0.49 ± 0.56° at 12 months (P = 0.04). The vertical metamorphopsia score improved significantly from 0.52 ± 0.53° at baseline to 0.33 ± 0.46° at 12 months (P = 0.005).
  
  
  CONCLUSIONS
  Half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy results in significant improvements of metamorphopsia at 1 year, especially in eyes with good best-corrected visual acuity at the baseline. Half-dose verteporfin photodynamic therapy can be a therapeutic option for patients with good visual acuity who complain of metamorphopsia.
authors.affiliation: *Department of Ophthalmology, Surugadai Nihon University Hospital, Tokyo, Japan; †Department of Ophthalmology, Teikyo University School of Medicine, University Hospital Mizonokuchi, Kawasaki-shi, Japan; and ‡Department of Ophthalmology, Teikyo University School of Medicine, University Hospital Itabashi, Tokyo, Japan.
authors.forename: Kyoko
authors.initials: K
authors.lastname: Fujita
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Imamura
authors.forename: Kei
authors.initials: K
authors.lastname: Shinoda
authors.forename: Celso Soiti
authors.initials: CS
authors.lastname: Matsumoto
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Mizutani
authors.forename: Atsushi
authors.initials: A
authors.lastname: Mizota
authors.forename: Mitsuko
authors.initials: M
authors.lastname: Yuzawa
mesh_terms: D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011166:Porphyrins / Q000008:administration & dosage*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014786:Vision Disorders / Q000175:diagnosis* / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin